Our Services
Medical Information
Helpful Resources
Published on: 9/13/2026
BlueChew's active ingredients, sildenafil and tadalafil, are generally considered safe for many men with stable heart conditions and for those taking common blood pressure drugs such as ACE inhibitors, ARBs, beta blockers, diuretics, and calcium channel blockers, but they can be dangerous or even life threatening when combined with nitrates like nitroglycerin, with riociguat, or in cases of recent heart attack or stroke, unstable angina, severe heart failure, or uncontrolled high or low blood pressure. Alpha blockers such as tamsulosin and doxazosin may also cause a sudden drop in blood pressure when paired with these medications, so timing and dosing matter. There are several important factors and drug interactions to weigh before starting, and they are explained below.
Because erectile dysfunction is often an early warning sign of underlying cardiovascular disease, understanding your own risk profile is worth a few minutes of your time; a free, instant, online symptom check can help you clarify what may be driving your symptoms and what questions to bring to a clinician before you take a first dose.
Last reviewed for medical accuracy: 09/12/2026
Is Blue Chew Safe for Your Heart or When You Take Blood Pressure Medication?
Blue Chew is a subscription service that delivers chewable tablets of sildenafil or tadalafil—two well-known phosphodiesterase-5 (PDE5) inhibitors used to treat erectile dysfunction (ED). If you’re taking blood pressure drugs or have aheart condition, it’s natural to wonder how Blue Chew might affect you. This guide reviews what cardiologists and pharmacologists say, based on credible sources such as the American Heart Association, major clinical trials, and FDA prescribing information.
This blood pressure-lowering effect is usually well tolerated in healthy men, but in certain situations it can be problematic.
Stable Heart Disease
Controlled Hypertension
No Nitrate Use
Even if you have no major heart disease, interactions with other medications can pose risks:
• Alpha-Blockers (e.g., tamsulosin, doxazosin)
– Both α-blockers and PDE5 inhibitors lower blood pressure.
– To reduce risk of dizziness or fainting, your doctor may start you on the lowest available dose of sildenafil/tadalafil and space it at least 4 hours apart from your alpha-blocker dose.
• Calcium Channel Blockers & Beta-Blockers
– Generally safe together, but monitor for signs of too-low blood pressure (lightheadedness, excessive fatigue).
– Your doctor may check your blood pressure at rest and after light exercise.
• Other Antihypertensives
– ACE inhibitors, ARBs, diuretics: combination is usually well tolerated.
– Watch for symptoms of low blood pressure, especially when standing up quickly.
If you fall into any of these categories, a thorough evaluation by your cardiologist or primary care physician is essential before starting Blue Chew.
Blood Pressure Checks
Symptom Logging
Regular Medical Reviews
Even mild symptoms can signal a need for medical advice:
Not all urgent issues occur in the doctor’s office. You might consider doing a free, online symptom check, using the doctor approved Ubie Symptom Checker. If symptoms are life-threatening—such as prolonged chest pain or collapsing—call 911 or go to your nearest emergency department.
Blue Chew can be safe for many men with well-managed blood pressure and stable heart disease if used under medical supervision. Key points to remember:
No online article can replace personalized medical advice. Always speak to a doctor before starting or adjusting any treatment that could affect your heart. If you experience severe or life-threatening symptoms, seek immediate medical attention.
(References)
* Schäfer S, Ellinghaus P, Janssen W, Kramer F, Lustig K, Milting H, Kast R, Klein M. Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling. Cardiovasc Res. 2009 Apr 1;82(1):30-9. doi: 10.1093/cvr/cvp002. Epub 2009 Jan 8. PMID: 19131365.
* Kukreja RC. Sildenafil and cardioprotection. Curr Pharm Des. 2013;19(39):6842-7. doi: 10.2174/138161281939131127110156. PMID: 23590161.
* Hoyerup P, Azawi NH. Partial priapism. BMJ Case Rep. 2013 Aug 9;2013. doi: 10.1136/bcr-2013-200031. Epub 2013 Aug 9. PMID: 23933863; PMCID: PMC3762157.
* Celik M, Aksoy AN, Aksoy H, Aksoy Y, Halici Z. Sildenafil reduces ischemia-reperfusion injury in rat ovary: biochemical and histopathological evaluation. Gynecol Obstet Invest. 2014;78(3):162-7. doi: 10.1159/000363747. Epub 2014 Jun 18. PMID: 24942826.
* Beghetti M, Rudzinski A, Zhang M. Efficacy and safety of oral sildenafil in children with Down syndrome and pulmonary hypertension. BMC Cardiovasc Disord. 2017 Jul 4;17(1):177. doi: 10.1186/s12872-017-0569-3. Epub 2017 Jul 4. PMID: 28676038; PMCID: PMC5496590.
* Samidurai A, Xi L, Das A, Kukreja RC. Beyond Erectile Dysfunction: cGMP-Specific Phosphodiesterase 5 Inhibitors for Other Clinical Disorders. Annu Rev Pharmacol Toxicol. 2023 Jan 20;63:585-615. doi: 10.1146/annurev-pharmtox-040122-034745. Epub 2022 Oct 7. PMID: 36206989.
* Edmonston D, Sparks M, Rajagopal S, Wolf M. Sildenafil and Kidney Function in Heart Failure with Preserved Ejection Fraction. Kidney360. 2023 May 1;4(5):631-640. doi: 10.34067/KID.0000000000000103. Epub 2023 Mar 29. PMID: 36978225; PMCID: PMC10278830.
* Webb AJS, Birks JS, Feakins KA, Lawson A, Dawson J, Rothman AMK, Werring DJ, Llwyd O, Stewart CR, Thomas J. Cerebrovascular Effects of Sildenafil in Small Vessel Disease: The OxHARP Trial. Circ Res. 2024 Jul 5;135(2):320-331. doi: 10.1161/CIRCRESAHA.124.324327. Epub 2024 Jun 4. PMID: 38832504; PMCID: PMC11227301.
* Jehle DVK, Sunesra R, Uddin H, Paul KK, Joglar AA, Michler OD, Blackwell TA, Gaalema D, Hayek S, Jneid H. Benefits of Tadalafil and Sildenafil on Mortality, Cardiovascular Disease, and Dementia. Am J Med. 2025 Mar;138(3):441-448.e3. doi: 10.1016/j.amjmed.2024.10.039. Epub 2024 Nov 10. PMID: 39532245.
* Le NN, Tran TQB, McClure J, Gill D, Padmanabhan S. Emerging antihypertensive therapies and cardiovascular, kidney, and metabolic outcomes: a Mendelian randomization study. Eur Heart J Cardiovasc Pharmacother. 2025 May 2;11(3):264-274. doi: 10.1093/ehjcvp/pvaf015. PMID: 39963705; PMCID: PMC12046581.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.